Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Centre Oscar Lambret
University of California, San Francisco
Columbia University
Olivia Newton-John Cancer Research Institute
University of Utah
Institut du Cancer de Montpellier - Val d'Aurelle
Imperial College London
Imperial College London
Imperial College London
Ohio State University Comprehensive Cancer Center
Washington University School of Medicine
Abramson Cancer Center at Penn Medicine
Fox Chase Cancer Center
University of Alberta
University of California, San Francisco
Grupo Espanol de Tumores Neuroendocrinos
University Hospital, Bordeaux
University of Iowa
University of Pittsburgh
Grupo Espanol de Tumores Neuroendocrinos
Erasmus Medical Center
Instituto do Cancer do Estado de São Paulo
University of Alberta
Melanoma and Skin Cancer Trials Limited
Peking University
Latin American Cooperative Oncology Group
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Grupo Espanol de Tumores Neuroendocrinos
Grupo Espanol de Tumores Neuroendocrinos
Beijing Chest Hospital
Abramson Cancer Center at Penn Medicine
Sunnybrook Health Sciences Centre
University of Sao Paulo
Case Comprehensive Cancer Center
European Institute of Oncology
Fundación de investigación HM
Memorial Sloan Kettering Cancer Center
Federation Francophone de Cancerologie Digestive
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
CHU de Quebec-Universite Laval
University Medical Center Goettingen
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
AC Camargo Cancer Center
Rigshospitalet, Denmark
AC Camargo Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Charite University, Berlin, Germany
SCRI Development Innovations, LLC